ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
6.78
+0.06 (0.89%)
Oct 10, 2025, 11:38 AM EDT - Market open
ImmuCell Revenue
ImmuCell had revenue of $6.44M in the quarter ending June 30, 2025, with 17.76% growth. This brings the company's revenue in the last twelve months to $28.27M, up 21.75% year-over-year. In the year 2024, ImmuCell had annual revenue of $26.49M with 51.64% growth.
Revenue (ttm)
$28.27M
Revenue Growth
+21.75%
P/S Ratio
2.09
Revenue / Employee
$376,997
Employees
75
Market Cap
61.33M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.49M | 9.02M | 51.64% |
Dec 31, 2023 | 17.47M | -1.10M | -5.90% |
Dec 31, 2022 | 18.57M | -675.01K | -3.51% |
Dec 31, 2021 | 19.24M | 3.90M | 25.43% |
Dec 31, 2020 | 15.34M | 1.62M | 11.80% |
Dec 31, 2019 | 13.72M | 2.74M | 24.91% |
Dec 31, 2018 | 10.99M | 555.21K | 5.32% |
Dec 31, 2017 | 10.43M | 887.13K | 9.30% |
Dec 31, 2016 | 9.54M | -684.73K | -6.69% |
Dec 31, 2015 | 10.23M | 2.63M | 34.64% |
Dec 31, 2014 | 7.60M | 1.59M | 26.46% |
Dec 31, 2013 | 6.01M | 617.24K | 11.45% |
Dec 31, 2012 | 5.39M | 278.79K | 5.45% |
Dec 31, 2011 | 5.11M | 724.95K | 16.53% |
Dec 31, 2010 | 4.39M | -119.56K | -2.65% |
Dec 31, 2009 | 4.51M | -122.55K | -2.65% |
Dec 31, 2008 | 4.63M | -1.44M | -23.74% |
Dec 31, 2007 | 6.07M | 1.27M | 26.41% |
Dec 31, 2006 | 4.80M | -181.87K | -3.65% |
Dec 31, 2005 | 4.98M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ICCC News
- 2 days ago - ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025 - GlobeNewsWire
- 10 days ago - ImmuCell Announces Selection of its Next President and CEO - GlobeNewsWire
- 2 months ago - ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025 - GlobeNewsWire
- 2 months ago - ImmuCell Announces Bank Debt Refinancing - GlobeNewsWire
- 2 months ago - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025 - GlobeNewsWire
- 3 months ago - ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025 - GlobeNewsWire
- 3 months ago - ImmuCell Embarks on CEO Succession Planning Process - GlobeNewsWire